Published: Tue, March 21, 2017
Economy | By Annette Adams

Seres Health, Inc. (NASDAQ:MCRB) Analyst Coverage

Seres Health, Inc. (NASDAQ:MCRB) Analyst Coverage

While there's significant promise for microbiome-based therapeutics, there's also market volatility because nobody knows how these companies will perform, said Michael Darcy, a senior business insights analyst at Decision Resources Group, a life sciences market research firm. Finally, Cowen and Company restated a "buy" rating on shares of Seres Therapeutics in a research report on Wednesday, February 1st. Seres reported a net loss of $25.3 million for the fourth quarter of 2016, as compared to a net loss of $19.6 million for the same period in 2015. Weighing on the stock is the company's lower-than-expected quarterly earnings, along with a full-year outlook cut.

Heading into the stock price potential, Seres Therapeutics, Inc. needs to grow just 24.58% to cross its median price target of $15. For the quarter ending Jun-17, 3 analysts have a mean sales target of 3.07 million whilst for the year ending Dec-17, 7 analysts have a mean target of 12.99 million. Zacks Investment Research lowered shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, January 11th.

Agile Therapeutics, Inc. (AGRX) opened the session with a $2.36 price tag, later ranging from $2.34 to $2.88, the range at which the stock has traded at throughout the day. The last close places the company's stock about $23.27 off its 52 week high of $35.98 and $4.66 above the 52 week low of $8.05. The company has an average rating of "Buy" and an average price target of $23.20.

The Stock now has the market capitalization of $515.64 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 9.83% and monthly volatility of 5.48% respectively. Ellington Management Group LLC acquired a new stake in Seres Therapeutics during the fourth quarter worth about $107,000.

The company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.70) by $0.07. Fidelity Management and Research Company is the second biggest holder with 6 million shares now valued at 60.47 million whilst Federated Global Inv Mgmt Corp has 2 million shares valued at 25.12 million. The firm had revenue of $3 million for the quarter, compared to analyst estimates of $3 million. Fox Run Management L.L.C. purchased a new position in Seres Therapeutics during the third quarter valued at $257,000. Renaissance Technologies LLC raised its stake in Seres Therapeutics by 35.0% in the fourth quarter.

Several large investors have recently modified their holdings of the company. Renaissance Technologies LLC now owns 400,300 shares of the company's stock worth $3,963,000 after buying an additional 103,800 shares in the last quarter.

ACI Worldwide, Inc. (NASDAQ:ACIW) announced that Peach Payments, a fast-growing South African payment service provider (PSP), will offer merchants a seamless mobile checkout solution with the ACI Mobile Commerce Software Development Kit (mSDK). "Our prior SER-109 studies provided important new biological and clinical data that have advanced our pioneering microbiome therapeutic efforts". The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Like this: